Aurum Ventures MKI

Scopio Labs Ltd., established in 2015 and headquartered in Tel Aviv, Israel, specializes in the development of digital microscopes utilizing computational imaging technologies. The company's innovative diagnostics platform enhances clinical workflows and supports the screening of cancer, hematology, and cytology, as well as academic research and drug discovery. Scopio Labs provides a suite of fully digital diagnostic applications that facilitate faster, more accurate detection and diagnosis of blood-related diseases, allowing hematology laboratories to efficiently assess and analyze cell morphology. This technology aims to improve the consistency and efficiency of the diagnostic process across the continuum of care.

KidneyCure Ltd. is a biotech company based in Tel Aviv, Israel, focused on developing innovative cell therapies to prevent the progression of Chronic Kidney Disease (CKD). Founded in 2009, the company aims to address renal cell depletion by administering autologous revitalized renal progenitor cells. KidneyCure's approach is founded on pioneering research conducted by Professor Benjamin Dekel at Sheba Medical Center, a leading medical institution in Israel. The company's proprietary 3D renal cell cluster technology is designed to significantly delay the necessity for dialysis and organ transplantation, ultimately offering millions of patients the prospect of longer and higher-quality lives.

Nucleix develops, manufactures, and markets non-invasive molecular cancer diagnostic tests. Its sensitive and specific tests are based on identification of subtle changes in methylation patterns. Nucleix offers a urine test for monitoring of bladder cancer called Bladder EpiCheck and a blood test for early detection of lung cancer called Lung EpiCheck. Adam Wasserstrom, Danny Frumkin, and Elon Ganor founded it in 2008, with its headquarters in Rehovot in Israel.

LifeBond Ltd. specializes in the development and manufacturing of absorbable bio-surgical medical devices aimed at enhancing tissue repair and improving patient recovery. Founded in 2006 and based in Caesarea, Israel, the company offers innovative products such as LifeSeal, a surgical sealant designed to reinforce staple lines in bariatric and colorectal surgeries, thereby minimizing complications like leakage. Another key product is LifeMesh, a self-fixating mesh intended for hernia repair, which is currently in pre-clinical development. LifeBond’s portfolio also includes tissue adhesives and absorbable hemostats. The company's devices are designed to meet various surgical needs, leveraging their natural origin, elasticity, adhesiveness, and durability. LifeBond's products are available in multiple regions, including China, the United States, and Europe, although they are still under investigation and have not received market approval.

CorAssist Cardiovascular Ltd. is a clinical stage medical device company based in Haifa, Israel, focused on developing innovative solutions for heart failure with preserved ejection fraction and diastolic dysfunction. The company's primary products include CORolla, an elastic self-expanding device designed to be implanted within the left ventricle using minimally invasive techniques. This device enhances diastolic function by improving filling performance without the need for an external power source. Another product, ImCardia, also an elastic self-expanding device, is designed to be attached to the external surface of the left ventricle through a straightforward off-pump procedure. Founded in 2003, CorAssist aims to advance therapeutic options for patients suffering from heart-related conditions.

BPT is developing and commercializing advanced membranes-based separation solutions addressing the unique needs of the water and wastewater treatment for key industrial processes. BPT patented chemically-stable membrane technology enable customers in the landfill, mining, chemical, biopharma and food industries to comply with the environmental regulations, reuse water and reduce production costs. BPT membranes are field proven to enable lowest cost reclamation of some of the most aggressive and vexing industrial waste water streams.